Antares Pharma to Present at the BMO 10th Annual Focus on Healthcare Conference

EWING, N.J.--(BUSINESS WIRE)-- Antares Pharma, Inc. (NYSE Amex: AIS) today announced that Robert F. Apple, EVP, CFO and President of the Parenteral Products Division will present at the BMO 10th Annual Focus on Healthcare Conference on Thursday, August 5, 2010 at 8:30 a.m. ET (Eastern Time).

An audio web cast of the presentation will be available under the investor relations section of the Antares website at www.antarespharma.com.

About Antares Pharma

Antares Pharma focuses on self-injection delivery technologies and topical gel-based pharmaceutical products. The Company's subcutaneous and intramuscular injection technology platforms include VIBEXTM disposable pressure-assisted auto injectors, ValeoTM/VisionTM reusable needle-free injectors, and disposable multi-use pen injectors. In the injector area, Antares Pharma has a multi-product deal with Teva Pharmaceutical Industries, Ltd that includes Tev-Tropin(R) human growth hormone and a partnership with Ferring Pharmaceuticals. In the gel-based area, the Company's lead product candidate is Anturol(R) an oxybutynin ATDTM gel for the treatment of OAB (overactive bladder)l. Antares also has a partnership with BioSante that includes LibiGel(R) (transdermal testosterone gel) in Phase 3 clinical development for the treatment of female sexual dysfunction (FSD), and Elestrin(R) (estradiol gel) indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and currently marketed in the U.S. Antares Pharma has corporate headquarters in Ewing, New Jersey, with subsidiaries performing research, development and product commercialization activities in Minneapolis, Minnesota and Muttenz, Switzerland.



CONTACT:

Antares Pharma, Inc.
Robert F. Apple
Chief Financial Officer
609-359-3020
or
Investors:
Westwicke Partners, LLC
John Woolford, 443-213-0506
[email protected]
or
Media:
Tiberend Strategic Advisors, Inc.
Tamara Bright, 212-827-0020
[email protected]

KEYWORDS:   United States  North America  New Jersey

INDUSTRY KEYWORDS:   Health  Biotechnology  Medical Devices  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.